Elixiron Immunotherapeutics (Cayman) Limited Company Description

Elixiron Immunotherapeutics (Cayman) Limited engages in the development of precision-targeted immunotherapy drugs in Shanghai, Taipei, the United States and Switzerland.

It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and Hemophagocytic Lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer.

Elixiron Immunotherapeutics (Cayman) Limited was incorporated in 2017 and is headquartered in Taipei, Taiwan.